VCs commit $50m to China's Medilink Therapeutics
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised $50 million in Series A funding across two tranches.
The first was led by Apricot Capital, a local healthcare investor founded in 2015 that has more than RMB3 billion ($463 million) in assets under management. The second came from Loyal Valley Capital and...
More on Greater China
Latest News
China home fitness brand Fiture raises $300m
Fiture, a Chinese developer of artificial intelligence-enabled home fitness devices, has raised $300 million in Series B funding led by All-Stars Investment, Legend Capital, DST Global, and Coatue Management.
Temasek leads $200m Series E for China's Arrail Dental
Arrail Group, one of China’s largest dental services providers, has raised close to $200 million in Series E funding led by Temasek Holdings.
China's TuSimple trades flat after $1.3b US IPO
TuSimple, a China and US-based developer of autonomous driving technology for trucks, traded flat on debut following a $1.35 billion IPO at a market capitalization of $8.5 billion.
Alpha JWC seeks $250m for third Indonesia VC fund
Alpha JWC Ventures is targeting $250 million for its third Indonesia-focused venture capital fund, with the International Finance Corporation (IFC) proposing a commitment of up to $20 million.